{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:09:58Z","timestamp":1785218998138,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"DOI":"10.7759\/cureus.61500","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T16:53:44Z","timestamp":1717260824000},"source":"Crossref","is-referenced-by-count":8,"title":["The Use of TNF-\u03b1 Inhibitors in Active Ankylosing Spondylitis Treatment"],"prefix":"10.7759","author":[{"given":"Georgios","family":"Zouris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios Stergios","family":"Evangelopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis S","family":"Benetos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vlamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Ankylosing spondylitis","author":"Wenker KJ","year":"2023","unstructured":"Wenker KJ, Quint JM. Ankylosing spondylitis. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.1.21","article-title":"Therapeutic advances in ankylosing spondylitis","volume":"10","author":"Toussirot E","year":"2001","unstructured":"Toussirot E, Wendling D. Therapeutic advances in ankylosing spondylitis. Expert Opin Investig Drugs. 2001, 10:21-9. 10.1517\/13543784.10.1.21","journal-title":"Expert Opin Investig Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun J","year":"2007","unstructured":"Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007, 369:1379-90. 10.1016\/S0140-6736(07)60635-7","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1258\/rsmsmj.52.4.32","article-title":"Ankylosing spondylitis","volume":"52","author":"Chee MM","year":"2007","unstructured":"Chee MM, Sturrock RD. Ankylosing spondylitis. Scott Med J. 2007, 52:32-5; quiz 35, 54. 10.1258\/rsmsmj.52.4.32","journal-title":"Scott Med J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-020-00948-3","article-title":"Janus kinase inhibitors for treating active ankylosing spondylitis: A\u00a0meta-analysis of randomized controlled trials","volume":"81","author":"Lee YH","year":"2022","unstructured":"Lee YH, Song GG. Janus kinase inhibitors for treating active ankylosing spondylitis: A\u00a0meta-analysis of randomized controlled trials. Z Rheumatol. 2022, 81:71-6. 10.1007\/s00393-020-00948-3","journal-title":"Z Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang DI","year":"2021","unstructured":"Jang DI, Lee AH, Shin HY, et al.. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci. 2021, 22:2719. 10.3390\/ijms22052719","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-015-0344-y","article-title":"Anti-TNF in rheumatoid arthritis: An overview","volume":"165","author":"Radner H","year":"2015","unstructured":"Radner H, Aletaha D. Anti-TNF in rheumatoid arthritis: An overview. Wien Med Wochenschr. 2015, 165:3-9. 10.1007\/s10354-015-0344-y","journal-title":"Wien Med Wochenschr"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0522-3","article-title":"Clinical tools to assess and monitor spondyloarthritis","volume":"17","author":"Landew\u00e9 R","year":"2015","unstructured":"Landew\u00e9 R, van Tubergen A. Clinical tools to assess and monitor spondyloarthritis. Curr Rheumatol Rep. 2015, 17:47. 10.1007\/s11926-015-0522-3","journal-title":"Curr Rheumatol Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/2050312116671725","article-title":"SF-36 total score as a single measure of health-related quality of life: Scoping review","volume":"4","author":"Lins L","year":"2016","unstructured":"Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016, 4:2050312116671725. 10.1177\/2050312116671725","journal-title":"SAGE Open Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.20","article-title":"Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis","volume":"62","author":"Doward LC","year":"2003","unstructured":"Doward LC, Spoorenberg A, Cook SA, et al.. Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003, 62:20-6. 10.1136\/ard.62.1.20","journal-title":"Ann Rheum Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091042","article-title":"A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis","volume":"37","author":"Inman RD","year":"2010","unstructured":"Inman RD, Maksymowych WP. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol. 2010, 37:1203-10. 10.3899\/jrheum.091042","journal-title":"J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852","article-title":"Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT)","volume":"52","author":"van der Heijde D","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J. Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005, 52:582-91. 10.1002\/art.20852","journal-title":"Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/art.22097","article-title":"Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo-controlled trial","volume":"55","author":"van der Heijde D","year":"2006","unstructured":"van der Heijde D, Han C, DeVlam K, et al.. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo-controlled trial. Arthritis Rheum. 2006, 55:569-74. 10.1002\/art.22097","journal-title":"Arthritis Rheum"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.11.1280","article-title":"Efficacy of infliximab in refractory ankylosing spondylitis: Results of a six-month open-label study","volume":"41","author":"Breban M","year":"2002","unstructured":"Breban M, Vignon E, Claudepierre P, et al.. Efficacy of infliximab in refractory ankylosing spondylitis: Results of a six-month open-label study. Rheumatology (Oxford). 2002, 41:1280-5. 10.1093\/rheumatology\/41.11.1280","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014258","article-title":"Infliximab therapy in patients with ankylosing spondylitis: An open label 12 month study","volume":"62","author":"Temekonidis TI","year":"2003","unstructured":"Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, Drosos AA. Infliximab therapy in patients with ankylosing spondylitis: An open label 12 month study. Ann Rheum Dis. 2003, 62:1218-20. 10.1136\/ard.2003.014258","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial","volume":"359","author":"Braun J","year":"2002","unstructured":"Braun J, Brandt J, Listing J, et al.. Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet. 2002, 359:1187-93. 10.1016\/S0140-6736(02)08215-6","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/art.11104","article-title":"Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial","volume":"48","author":"Braun J","year":"2003","unstructured":"Braun J, Brandt J, Listing J, et al.. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. 2003, 48:2224-33. 10.1002\/art.11104","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh584","article-title":"Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years","volume":"44","author":"Braun J","year":"2005","unstructured":"Braun J, Baraliakos X, Brandt J, et al.. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford). 2005, 44:670-6. 10.1093\/rheumatology\/keh584","journal-title":"Rheumatology (Oxford)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"van der Heijde D","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, et al.. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006, 54:2136-46. 10.1002\/art.21913","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/art.22887","article-title":"Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study","volume":"57","author":"Davis JC Jr","year":"2007","unstructured":"Davis JC Jr, Revicki D, van der Heijde DM, Rentz AM, Wong RL, Kupper H, Luo MP. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study. Arthritis Rheum. 2007, 57:1050-7. 10.1002\/art.22887","journal-title":"Arthritis Rheum"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087270","article-title":"Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: Long-term results from the ATLAS trial","volume":"68","author":"van der Heijde D","year":"2009","unstructured":"van der Heijde D, Schiff MH, Sieper J, et al.. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: Long-term results from the ATLAS trial. Ann Rheum Dis. 2009, 68:922-9. 10.1136\/ard.2007.087270","journal-title":"Ann Rheum Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/ar2790","article-title":"Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis","volume":"11","author":"van der Heijde DM","year":"2009","unstructured":"van der Heijde DM, Revicki DA, Gooch KL, et al.. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther. 2009, 11:R124. 10.1186\/ar2790","journal-title":"Arthritis Res Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu438","article-title":"Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab","volume":"54","author":"van der Heijde D","year":"2015","unstructured":"van der Heijde D, Breban M, Halter D, et al.. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Rheumatology (Oxford). 2015, 54:1210-9. 10.1093\/rheumatology\/keu438","journal-title":"Rheumatology (Oxford)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.082529","article-title":"Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis","volume":"67","author":"van der Heijde D","year":"2008","unstructured":"van der Heijde D, Pangan AL, Schiff MH, et al.. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis. 2008, 67:1218-21. 10.1136\/ard.2007.082529","journal-title":"Ann Rheum Dis"},{"key":"ref25","article-title":"Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis","volume":"35","author":"Maksymowych WP","year":"2008","unstructured":"Maksymowych WP, Rahman P , Shojania K, et al.. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol. 2008, 35:2030-7.","journal-title":"J Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081048","article-title":"Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis","volume":"36","author":"Rudwaleit M","year":"2009","unstructured":"Rudwaleit M, Claudepierre P, Wordsworth P, et al.. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009, 36:801-8. 10.3899\/jrheum.081048","journal-title":"J Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: Results of a randomised, controlled trial","volume":"73","author":"Huang F","year":"2014","unstructured":"Huang F, Gu J, Zhu P, et al.. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: Results of a randomised, controlled trial. Ann Rheum Dis. 2014, 73:587-94. 10.1136\/annrheumdis-2012-202533","journal-title":"Ann Rheum Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1525024","article-title":"Real-world effectiveness and safety of adalimumab for treatment of ankylosing spondylitis in Japan","volume":"29","author":"Kobayashi S","year":"2019","unstructured":"Kobayashi S, Kashiwagi T, Kimura J. Real-world effectiveness and safety of adalimumab for treatment of ankylosing spondylitis in Japan. Mod Rheumatol. 2019, 29:1007-12. 10.1080\/14397595.2018.1525024","journal-title":"Mod Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin A","year":"2004","unstructured":"Calin A, Dijkmans BA, Emery P, et al.. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis. 2004, 63:1594-600. 10.1136\/ard.2004.020875","journal-title":"Ann Rheum Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081033","article-title":"Etanercept in the longterm treatment of patients with ankylosing spondylitis","volume":"36","author":"Dijkmans B","year":"2009","unstructured":"Dijkmans B, Emery P, Hakala M, et al.. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol. 2009, 36:1256-64. 10.3899\/jrheum.081033","journal-title":"J Rheumatol"},{"key":"ref31","article-title":"Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis","volume":"28","author":"Mart\u00edn-Mola E","year":"2010","unstructured":"Mart\u00edn-Mola E, Sieper J, Leirisalo-Repo M, et al.. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2010, 28:238-45.","journal-title":"Clin Exp Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial","volume":"48","author":"Davis JC Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, et al.. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum. 2003, 48:3230-6. 10.1002\/art.11325","journal-title":"Arthritis Rheum"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.035105","article-title":"Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks","volume":"64","author":"Davis JC","year":"2005","unstructured":"Davis JC, van der Heijde DM, Braun J, et al.. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis. 2005, 64:1557-62. 10.1136\/ard.2004.035105","journal-title":"Ann Rheum Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.078139","article-title":"Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis","volume":"67","author":"Davis JC Jr","year":"2008","unstructured":"Davis JC Jr, van der Heijde DM, Braun J, et al.. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008, 67:346-52. 10.1136\/ard.2007.078139","journal-title":"Ann Rheum Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt J","year":"2003","unstructured":"Brandt J, Khariouzov A, Listing J, et al.. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003, 48:1667-75. 10.1002\/art.11017","journal-title":"Arthritis Rheum"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/art.21588","article-title":"Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data","volume":"53","author":"Baraliakos X","year":"2005","unstructured":"Baraliakos X, Brandt J, Listing J, et al.. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data. Arthritis Rheum. 2005, 53:856-63. 10.1002\/art.21588","journal-title":"Arthritis Rheum"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/ar4244","article-title":"Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years","volume":"15","author":"Baraliakos X","year":"2013","unstructured":"Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther. 2013, 15:R67. 10.1186\/ar4244","journal-title":"Arthritis Res Ther"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180718","article-title":"Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: Results through 1 year of the GO-ALIVE study","volume":"46","author":"Reveille JD","year":"2019","unstructured":"Reveille JD, Deodhar A, Caldron PH, et al.. Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: Results through 1 year of the GO-ALIVE study. J Rheumatol. 2019, 46:1277-83. 10.3899\/jrheum.180718","journal-title":"J Rheumatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.04.1837","article-title":"Effects of intravenous golimumab on health-related quality of life in patients with ankylosing spondylitis: 28-week results of the GO-ALIVE Trial","volume":"23","author":"Reveille JD","year":"2020","unstructured":"Reveille JD, Deodhar A, Ince A, et al.. Effects of intravenous golimumab on health-related quality of life in patients with ankylosing spondylitis: 28-week results of the GO-ALIVE Trial. Value Health. 2020, 23:1281-5. 10.1016\/j.jval.2020.04.1837","journal-title":"Value Health"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman RD","year":"2008","unstructured":"Inman RD, Davis JC Jr, Heijde Dv, et al.. Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008, 58:3402-12. 10.1002\/art.23969","journal-title":"Arthritis Rheum"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131003","article-title":"The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial","volume":"41","author":"van der Heijde D","year":"2014","unstructured":"van der Heijde D, Deodhar A, Braun J, et al.. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol. 2014, 41:1095-103. 10.3899\/jrheum.131003","journal-title":"J Rheumatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu132","article-title":"Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial","volume":"53","author":"Bao C","year":"2014","unstructured":"Bao C, Huang F, Khan MA, Fei K, Wu Z, Han C, Hsia EC. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology (Oxford). 2014, 53:1654-63. 10.1093\/rheumatology\/keu132","journal-title":"Rheumatology (Oxford)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9 R","year":"2014","unstructured":"Landew\u00e9 R, Braun J, Deodhar A, et al.. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014, 73:39-47. 10.1136\/annrheumdis-2013-204231","journal-title":"Ann Rheum Dis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/art.38973","article-title":"Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: Results from a phase III randomized trial","volume":"67","author":"Sieper J","year":"2015","unstructured":"Sieper J, Landew\u00e9 R, Rudwaleit M, et al.. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: Results from a phase III randomized trial. Arthritis Rheumatol. 2015, 67:668-77. 10.1002\/art.38973","journal-title":"Arthritis Rheumatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22594","article-title":"Impact of certolizumab pegol on patient-reported outcomes in patients with axial spondyloarthritis","volume":"67","author":"Sieper J","year":"2015","unstructured":"Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, Landew\u00e9 R. Impact of certolizumab pegol on patient-reported outcomes in patients with axial spondyloarthritis. Arthritis Care Res (Hoboken). 2015, 67:1475-80. 10.1002\/acr.22594","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/257337-the-use-of-tnf--inhibitors-in-active-ankylosing-spondylitis-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T16:53:48Z","timestamp":1717260828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/257337-the-use-of-tnf--inhibitors-in-active-ankylosing-spondylitis-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.61500","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}